33results about How to "Inhibit expression" patented technology

The application discloses a sensitized ferroptosis lipid nano regulator and a preparation method and application thereof, and belongs to the technical field of new adjuvants and new dosage forms of drug preparation combined treatment. The lipid nano regulator is co-assembled by a GPX4 inhibitor and a FASN inhibitor through intermolecular forces, and is modified with an oxidation-reduction sensitive PEG modifier, a molar ratio of the GPX4 inhibitor and the FASN inhibitor is 10:1-1:10, a mass ratio of the sum of the GPX4 inhibitor and the FASN inhibitor to the PEG modifier is 10:90-90:10, and the intermolecular forces include pi-pi stacking force, hydrophobic force and hydrogen bond. The co-assembled nano preparation provides a new strategy and more choices for the development of drug delivery, and meets the urgent needs of high-efficiency and diverse ferroptosis treatment strategies in preparations in the clinic.

This invention discloses an enzyme- and pH-responsive nucleic acid loading and delivery material and its preparation method. The material can be used for efficient loading and delivery of nucleic acid molecules. The preparation method uses amphiphilic zwitterionic monomers to improve the reverse emulsion polymerization system, enhancing polymerization at the two-phase interface and avoiding the extrusion effect of polymerization in the aqueous core on nucleic acid molecules, thereby improving the loading efficiency of nucleic acid molecules. Further preparation of cross-linking agents MP-CL and CB-CL, which can cleave in response to matrix metalloproteinase II or cathepsin B, endows the nanogel with the ability to respond to charge reversal in the tumor matrix and to release nucleic acid molecules from tumor cells. The acid-sensitive blocks on the amphiphilic monomers give the nanogel lysosomal escape capability. The delivery material can efficiently deliver nucleic acid molecules into cells and exhibits excellent stability and biosafety.

The invention discloses an injectable hydrogel pharmaceutical composition for an articular cavity as well as a preparation method and application of the injectable hydrogel pharmaceutical composition. The hydrogel pharmaceutical composition comprises gel particles and a medicine loaded in the gel particles, the gel particles are formed by cross-linking hyaluronic acid or salt thereof and silk fibroin through a cross-linking agent; the medicine comprises an anti-inflammatory drug and / or a growth factor. The preparation method is simple, good in safety and beneficial to industrial production. The uniform porous structure of the hydrogel is beneficial to adhesion and growth of bone cells, meanwhile, the double-load hydrogel loaded with the anti-inflammatory drug and the growth factor has good viscoelasticity and injectability and has the effects of synergistically resisting inflammation and promoting cartilage repair, and bone joint related diseases are treated in a bone joint intracavity injection mode; the drug residence time can be prolonged, and the bioavailability is improved.

The application belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine compound for treating pulmonary fibrosis of diabetes and application thereof. The traditional Chinese medicine compound comprises 70-90 parts of Huangqi, 20-40 parts of Danshen, 10-30 parts of Chuanxiong, 20-40 parts of Beishashen and 40-60 parts of Shanyao. The application also discloses application of the traditional Chinese medicine compound in preparation of a medicine for treating pulmonary fibrosis of diabetes of the type of deficiency of both qi and yin and blood stasis. The traditional Chinese medicine compound has reasonable formula, and uses the traditional Chinese medicine theory scientifically. The raw materials are matched according to the principle of monarch, minister, assistant and guide, and the traditional Chinese medicines are synergistically used, so that the traditional Chinese medicine compound can not only supplement deficiency of both qi and yin of diabetes, but also dredge stasis of collaterals of long-term disease, and achieve good clinical test effect by considering both the symptoms and the root cause.

This invention discloses the application of a reagent that inhibits ADNP gene expression or ADNP protein activity in the preparation of drugs for treating renal fibrosis, belonging to the field of biomedical technology. The application of the reagent that inhibits ADNP gene expression or ADNP protein activity in the preparation of drugs for treating renal fibrosis. This invention effectively knocks down or knocks out the ADNP gene in renal tubular epithelial cells, objectively investigates the effects of ADNP deficiency on a series of phenotypes in HK-2 cells, and confirms that ADNP can inhibit EMT and renal fibrosis in HK-2 cells. Drugs that target and knock down or knock out the ADNP gene in human kidneys can be developed to delay the progression of renal fibrosis.

The application belongs to the technical field of biomaterial preparation, and particularly relates to a composite drug delivery system based on macrophage membranes and a preparation method and application thereof. The composite drug delivery system takes a lipid nanoparticle as a drug targeting delivery carrier, coats quercetin through an active phagocytosis mode, coats a macrophage membrane on the surface of the lipid nanoparticle, and constructs a quercetin lipid nanoparticle coated with a macrophage membrane (MCM@QU@LNP). The composite drug delivery system provided by the application can promote drug enrichment in RA lesions, improve local drug exposure, realize precise drug delivery in the RA part, has good biological safety, and reduces system toxicity.

This invention discloses a cyclic nonapeptide with both anti-photoaging and antioxidant effects. The amino acid sequence of the cyclic nonapeptide is: cyclic (arginine-glycine-aspartic acid-serine-asparagine-lysine-valine-lysine-phenylalanine). The cyclic nonapeptide of this invention can effectively reduce deep photoaging caused by UVA and surface oxidative damage induced by UVB, thereby achieving comprehensive skin protection.

The application discloses an interfering RNA for inhibiting ALDH2 gene expression and application, belongs to the field of gene biological medicine, and relates to the interfering RNA, wherein the double-stranded siRNA comprises a sense strand and an antisense strand, and the double-stranded siRNA is selected from any one of SEQ ID NO. 1-2, SEQ ID NO. 3-4 and SEQ ID NO. 5-6. The interfering RNA can effectively inhibit ALDH2 gene expression in colorectal cancer cells, provides a new choice for preventing or treating colorectal cancer carrying an APC gene defect / mutation based on the principle of synthetic lethality, and provides a new target for drug research and development for rectal cancer treatment.

This application discloses a composition containing palmitoyl tripeptide-5, a skin care product, and its uses. The composition containing palmitoyl tripeptide-5 comprises acetyl tripeptide-30 citrulline and palmitoyl tripeptide-5 in a mass ratio of (1.5-2):2. The composition containing palmitoyl tripeptide-5 can protect the skin through the synergistic effect of acetyl tripeptide-30 citrulline and palmitoyl tripeptide-5.

This application relates to the biomedical field, specifically to a GalNAc delivery molecule and its applications. This application provides a GalNAc-oligonucleotide conjugate having the structure shown in Formula I or Formula II. The GalNAc-oligonucleotide conjugate and its drug provided in this application have high delivery efficiency, enabling the delivery of oligonucleotides to the liver to inhibit the expression of target genes, thereby reducing the expression level of target proteins in the liver and providing a new approach for treating liver-related diseases.

This invention provides the application of costunolide in the preparation of a drug for preventing posterior capsule opacification. Costunolide effectively reduces posterior capsule opacification after extracapsular lens extraction (ECLE) and exhibits significant anti-inflammatory and anti-fibrotic effects in both in vitro and in vivo models. Mechanistic studies have identified matrix metalloproteinase 8 (MMP8) as a key downstream effector of costunolide, confirming that costunolide inhibits MMP8 expression, thereby blocking the transformation of lens epithelial cells (LECs) into mesenchymal cells and subsequent fibrotic processes. This lays a solid foundation for developing targeted therapies for posterior cataract, a common surgical complication.

This disclosure pertains to the field of biomedicine, specifically relating to double-stranded oligonucleotides targeting the APP gene and their applications. Specifically, it provides double-stranded oligonucleotide agents or their salts, conjugates, or compositions for inhibiting amyloid precursor protein (APP) expression, wherein the double-stranded oligonucleotide agent comprises a sense strand and an antisense strand forming a double-stranded region; wherein the antisense strand sequence comprises at least 15 consecutive nucleotides of any of the sequences shown in SEQ ID NO:1-154 with a difference of no more than 3 nucleotides, and / or the sense strand sequence comprises at least 15 consecutive nucleotides of any of the sequences shown in SEQ ID NO:155-308 with a difference of no more than 3 nucleotides. The double-stranded oligonucleotide agent or its salt for inhibiting APP expression disclosed in this application can significantly inhibit APP expression and can be used for the prevention and / or treatment of diseases or conditions mediated by the APP gene and / or associated with protein amyloidosis.

The invention belongs to the field of nucleic acid reagents, and particularly relates to a reagent and a method for silencing HIF2A. The dsRNA reagent provided by the invention can efficiently inhibit the expression of the HIF2A, so that the dsRNA reagent can be used for treating or preventing diseases related to the HIF2A, such as cancers, cardiovascular diseases and pulmonary arterial hypertension.

This invention belongs to the field of protein technology and relates to a peptide that prevents collagen loss and its preparation method. The amino acid sequence of the peptide is KSYELPDGQVITIG, with the key active fragment being ELPDGQVIT. The peptide is obtained by enzymatic hydrolysis of defatted grain insect powder using alkaline protease, trypsin, papain, neutral protease, and flavor protease. This peptide can inhibit the expression of MMP1 and MMP9 in L929 cells after UVA irradiation, thus alleviating collagen loss.

The application discloses application of an sEH inhibitor in preparation of a medicine for treating IgA nephropathy. The application proposes that an sEH inhibitor (such as t-AUCB, N-benzyl linoleamide) is used to inhibit sEH activity, restore the level of endogenous anti-inflammatory mediator epoxyeicosatrienoic acid (EETs), and rebuild the EETs / DiHETs metabolic balance. Experiments prove that the sEH inhibitor can significantly reduce the urine albumin / creatinine ratio of an IgA nephropathy model mouse, improve the blood urea and creatinine levels, and reduce glomerular IgA deposition. Mechanically, the therapy can restore the EETs level, down-regulate the content of hydrolysis product DiHETs, rebuild the EETs / DiHETs metabolic balance, and then inhibit the expression of renal IL-1beta, IL-6, TNF-alpha and other pro-inflammatory factors. It is clear that the sEH / EET axis is a key pathogenic pathway of IgA nephropathy, and a novel metabolic targeting strategy is provided for developing a specific medicine for treating IgA nephropathy.

The application belongs to the field of medicine and biotechnology, and particularly relates to application of a substance for reducing KDM1A content or activity in preparation of a product for treating non-alcoholic fatty liver disease and related diseases. In the application, the substance for reducing KDM1A content or activity in preparation of the product for treating non-alcoholic fatty liver disease and related diseases is at least one selected from a KDM1A protein content or activity reducing inhibitor, a KDM1A mRNA content or activity reducing inhibitor, and a CRISPR-Cas9 gene knockout system targeting a KDM1A gene. The application finds a new use of the KDM1A gene, and inhibiting expression of KDM1A protein or inhibiting KDM1A protein or inhibiting mRNA level of KDM1A in cells or tissues can play a role in protecting the liver and inhibiting non-alcoholic fatty liver disease.

This disclosure belongs to the field of pharmaceutical technology, and specifically relates to the application of targeted proline metabolic enzymes in the treatment of endometriosis. This disclosure, through in vitro experiments and EMS animal models, verifies that the proline content in ectopic endometrial stromal cells increases, the expression of proline synthesis metabolic enzymes is elevated, and fibrosis is significantly activated. This disclosure creatively repurposes proline metabolic enzyme inhibitors for EMS treatment. Proline metabolic enzyme inhibitors specifically inhibit the enzyme activity of key proline metabolism enzymes, blocking the synthesis pathway from glutamate to proline, and directly reducing intracellular proline content. Since proline is a major component amino acid of collagen, the inhibition of proline synthesis directly inhibits collagen synthesis and the expression of fibrosis markers in endometrial stromal cells, ultimately achieving the therapeutic effect of inhibiting fibrosis in EMS ectopic lesions and reducing ectopic lesion growth.

The invention relates to scutellarin-loaded brain tissue exosome nanoparticles and application thereof in preparation of a medicine for treating diseases by penetrating through a blood brain barrier, and belongs to the technical field of medicines. Brain tissue exosome nanoparticles loaded with scutellarin are added into mouse microglial cells, astrocytes and brain microvascular endothelial cells, so that the nanoparticles can regulate the polarization of the microglial cells caused by PRV infection, remarkably inhibit the expression of M1 type microglial cells CD86, promote the expression of M2 type microglial cells CD 206, inhibit the expression of the PRV infection, and inhibit the PRV infection. The anti-inflammatory effect is achieved; through in-vitro Transwell blood brain barrier and blood brain barrier penetration test of the exosome of a living brain tissue model, it is obtained that the brain tissue exosome can enhance the brain delivery efficiency of scutellarin. The scutellarin-loaded brain tissue exosome nanoparticles provided by the invention solve the problems of difficult scutellarin blood brain barrier penetration and low bioavailability, and have important practical significance in prevention and control of porcine pseudorabies.

This application provides nanoparticles with specific RNA cleaving activity, their preparation method, and applications, belonging to the field of biomedical technology. The nanoparticles, formed by the self-assembly of folic acid and lanthanum trichloride through coordination bonds, not only possess extremely high cleavage activity and stability, strong targeting, and good biocompatibility, but also integrate multiple functions including "targeted recognition-intracellular delivery-RNA cleavage".

The application relates to the field of implant technology, and particularly relates to a dental implant with a high-bioactivity surface coating and a preparation method thereof; in order to improve the bioactivity of a dental implant and improve the healing condition of the dental implant after implantation, the dental implant surface is first subjected to sand blasting treatment for roughening and acid liquid and alkali liquid immersion treatment, the content of hydroxyl groups on the surface of the dental implant is increased, the hydrophilicity of the dental implant is improved, the content of active groups on the surface of the dental implant is increased, and on this basis, a polydopamine coating containing exosome microcapsules is introduced into the surface of the dental implant, so that the antibacterial performance of the dental implant is improved and the proliferation of cells is induced, the implantation of the dental implant is accelerated, and the bioaffinity of the dental implant is greatly improved.

The invention relates to the technical field of crossing of a stem cell engineering technology, a nano-drug delivery system and a gene therapy technology, in particular to a PEI-LNPmiR-21 delivery system, a preparation method and application thereof and an engineered long-acting stem cell preparation. According to the delivery system, a lipid nanoparticle core is prepared by adopting a microfluidic technology, and low-molecular-weight PEI is covalently grafted on the surface of a lipid layer by utilizing carbodiimide chemistry, so that a nano compound with a core-shell structure is formed. The compound can efficiently deliver miR-21 into stem cells, and by regulating and controlling a PTEN / PI3K / Akt signal channel, the expression of a cell aging marker is remarkably inhibited, the proliferation capacity of the stem cells is enhanced, and the stemness characteristic of the stem cells is maintained.

This invention discloses a shuttle peptide targeting YY1S247 phosphorylation and its application. The sequence of the shuttle peptide is shown in SEQ ID NO: 1. RQIKIWFQNRRMKWKK is a part of the Drosophila melanogaster tentacles peptide, used to provide cell penetration; PKKKRKV is the nuclear localization sequence of the SV40 large T antigen, used to guide the peptide into the cell nucleus; QIIGENSPPDYSE is the surrounding sequence of the YY1S247 site. The results show that the shuttle peptide (CPP) of this invention can competitively and specifically inhibit phosphorylation at the YY1S247 site, thereby inhibiting CD24 expression and enhancing the therapeutic effect of EGFR-TKIs.

The invention discloses a red light reversible regulation gene expression system and application, the system comprises three plasmid vectors, respectively a plasmid pPA formed by fusing a PUF protein and a phytochrome PhyA, a plasmid pFE formed by fusing a shuttle protein FHY1 and eIF4E, and a downstream targeting regulation plasmid pNG formed by an NRE target and a downstream gene of interest GOI; according to the invention, the binding characteristic of RNA binding protein PUF and target NRE thereof is utilized, and the characteristic of dimerization of PhyA protein and ligand FHY1 thereof under red light is fused, so that a gene expression activation system capable of bidirectional light regulation is constructed, the PUF protein continuously and stably inhibits expression of downstream genes of interest, background leakage of the system is reduced from the source, and the expression of the downstream genes of interest is inhibited. Expression of downstream interested genes can be caused only under irradiation of red light, the expression can be rapidly closed by far-red light, and the expression of the genes can be accurately controlled through light; the system can be applied to tumor treatment.

The present application relates to an asymmetric RNAi-inducing nucleic acid molecule which inhibits the expression of retinoid-related orphan nuclear receptor-beta (ROR-beta) and use thereof, and more particularly to an asymmetric RNAi-inducing nucleic acid molecule comprising an antisense strand comprising a sequence complementary to mRNA encoding ROR-beta, and a sense strand forming complementary bonds with the antisense strand, and a pharmaceutical composition for ameliorating or treating a retinal disease, comprising the asymmetric RNAi-inducing nucleic acid molecule.

The application relates to the technical field of genetic engineering, and discloses a recombinant human collagen type III and a preparation method and application thereof, the amino acid sequence of the recombinant human collagen type III comprises the amino acid sequence shown in SEQ ID NO. 1, the amino acid sequence of the recombinant human collagen type III provided by the application has the characteristics of high hydrophilicity and uniform charge distribution, and the characteristics greatly improve the transdermal absorption efficiency of the product, so that the product can penetrate into the bottom layer of the skin more deeply and has better efficacy. Meanwhile, the 100% humanized amino acid sequence design of the product ensures high affinity of the product with the human skin and maximally reduces the risk of allergic reaction.

This invention belongs to the field of pharmaceutical technology and discloses the inhibitory effects and mechanisms of action of sclerotinib on lung cancer cells, cervical cancer cells, and ovarian cancer cells. Compared with the currently available broad-spectrum antitumor drug fluorouracil, sclerotinib exhibits superior antitumor properties. In-depth research revealed that sclerotinib acts on the novel protein STAT3 in cancer treatment, inhibiting STAT3 phosphorylation and preventing phosphonate-modified protein dimers from entering the cell nucleus to initiate transcription. Furthermore, sclerotinib inhibits the downstream anti-apoptotic protein BCL-2 of STAT3, synergistically inhibiting tumor cell proliferation. In this study, based on the half-maximal inhibitory concentration (IC50) results of sclerotinib against lung cancer cells A549, cervical cancer cells HeLa, and ovarian cancer cells A2780, we directly verified the anticancer target of sclerotinib through experiments, elucidated its anticancer mechanism, and provided theoretical and experimental basis for its entry into preclinical and clinical trials.

The invention relates to a whitening and freckle-removing skin care product composition and a preparation method thereof, and belongs to the field of cosmetics. The composition is prepared from the active ingredients such as the bifid yeast fermentation product filtrate, the glycyrrhiza glabra extract and the curcuma zedoaria root extract, and the active ingredients are matched with one another, so that the composition is endowed with excellent effects of whitening, removing freckles, preserving moisture, resisting inflammation and the like.

The invention discloses application of an HDGF (High Density Growth Factor) inhibiting gene in preparation of a lung cancer radiotherapy sensitization drug, the drug is prepared based on an HDGF inhibiting gene method, chemical components of the drug comprise a small interfering RNA (Ribonucleic Acid) component carrying the HDGF gene, the HDGF inhibiting gene method is realized through liposome mediated small interfering RNA, and the HDGF gene is used for reducing or preventing HDGF. The liposome-mediated small interfering RNA is transfected into human non-small cell lung cancer A549 and H522 cells, so that the expression of HDGF genes is successfully inhibited, a PI 3K / AKT signal channel is inhibited, the growth and proliferation speed of lung cancer cells is inhibited, the sensitivity of the lung cancer cells to radiation is improved, and the lung cancer cells can be used for treating lung cancer. The growth inhibition effect of liposome-mediated small interfering RNA transfection combined radiotherapy on lung cancer cells is higher than that of a single small interfering RNA transfection group and a single radiotherapy group, and an obvious radiotherapy sensitization effect is shown.

The invention belongs to the technical field of biology, and particularly relates to a dsRNA synergist, and application and a method of the dsRNA synergist in improving the RNAi efficiency of lepidoptera pests. By analyzing factors influencing the RNAi efficiency of the ostrinia furnacalis, a gene which can be induced to be up-regulated by dsRNA and is named as REX4 gene is found, REX4 protein coded by the gene is found to be capable of directly degrading the dsRNA under in-vitro conditions, the degradation efficiency is relatively high, aspartic acid at a first catalytic site is mutated into glycine, and the gene can be used for degrading the dsRNA at a second catalytic site. And the nucleic acid degradation capability of the REX4 protein is obviously reduced. Insect RNAi efficiency can be improved by inhibiting expression of the REX4 gene, and the gene generally exists in lepidoptera insects. The REX4 protein provided by the invention can be used as a core target for improving the RNAi efficiency of the lepidoptera pests, the problem of low RNAi efficiency of the lepidoptera pests is solved, and the application of the RNAi technology in agricultural pest control is promoted.